Lobaplatin in Prophylactic Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer: Safety and Efficacy Profiles

Figures & data

Table 1 Clinical Characteristics

Variables	HIPEC Group (n=61)	Non-HIPEC Group (n=68)	p
Gender			0.725
Male	32 (52.5)	33 (48.5)
Female	29 (47.5)	35 (51.5)
Age (range, years)	52.4±10.7 (28–72)	53.1±10.5 (25–70)	0.725
BMI (range, kg/m^2)	23.7±2.2 (18.75–27.76)	24.2±2.3 (20.15–30.42)	0.206
ASA score			0.733
1	25 (41.0)	27 (39.7)
2	30 (49.2)	32 (47.1)
3	6 (9.8)	9 (13.2)
Clinical T stage			0.824
T3	37 (60.7)	38 (55.9)
T4	24 (39.3)	30 (44.1)
Clinical N positivity	26 (42.6)	25 (36.8)	0.589
Gastrectomy			0.531
Proximal	10 (16.4)	14 (20.6)
Distal	40 (65.6)	38 (55.9)
Total	11 (18.0)	16 (23.5)
Anastomotic methods			0.550
Billroth I	15 (24.6)	12 (17.6)
Billroth II	25 (41.0)	26 (38.2)
Roux-en-Y	11 (18.0)	16 (23.5)
Estimated blood loss (range; mL)	105.6±37.5 (50–220)	97.3±32.6 (60–200)	0.180
Overall operating time (range; min)	178.0±22.3 (140–220)	171.8±18.5 (130–240)	0.089
Pathological TNM stage			0.585
II	24 (39.3)	30 (44.1)
III	37 (60.7)	38 (55.9)

Notes: HIPEC, hyperthermic intraperitoneal chemotherapy; BMI, body mass index; ASA, American Society of Anesthesiologists; TNM, tumor-node-metastasis.

Table 2 Postoperative Recovery

Variables	HIPEC Group (n=61)	No HIPEC Group (n=68)	p
Time to first flatus (range; d)	2.2±1.0 (1.2–8)	2.1±0.8 (1.4–7)	0.529
Time to first oral intake (range; d)	2.6±1.1 (1.9–9)	2.4±1.0 (1.6–8)	0.389
Postoperative complications (n; %)
Duodenal stump/anastomotic leakage	3 (4.9)	3 (4.4)	1.000
Intestinal obstruction	2 (3.3)	1 (1.5)	0.602
Abdominal bleeding	1 (1.6)	4 (5.9)	0.369
Abdominal infection	3 (4.9)	4 (5.9)	1.000
Lung infection	2 (3.3)	0 (0)	0.222
Incision infection	5 (8.2)	4 (5.9)	0.735
High fever	4 (6.6)	2 (2.9)	0.421
Abnormal routine blood tests	2 (3.3)	0 (0)	0.222
Abnormal liver function tests	0 (0)	1 (1.5)	1.000
Abnormal renal function tests	0 (0)	0 (0)	N/A
Allergic reaction	1 (1.6)	0 (0)	0.473
Neurotoxicity	0 (0)	0 (0)	N/A
Re-operation (n,%)	2 (3.3)	2 (2.9)	1.000
Perioperative death (n, %)	0 (0)	0 (0)	N/A
Postoperative hospital stay (range; d)	7.7±1.5 (5–14)	7.5±1.3 (6–12)	0.423

Notes: HIPEC, hyperthermic intraperitoneal chemotherapy. Abnormal routine blood tests refer to peripheral blood leukocyte counts ˂3500/mm³ or platelet counts ˂80,000/mm.³ Abnormal liver function tests refer to serum bilirubin level >3 or liver enzymes >3 times ULN. Abnormal renal function tests refer to serum creatinine levels >1.5 mg/dl.

Table 3 Survival Outcomes

Variables	HIPEC Group (n=61)	Non-HIPEC Group (n=68)	p
Postoperative chemotherapy (%)	54 (88.5)	60 (88.2)	1.000
Peritoneal cavity recurrence (%)	3 (4.9)	12 (17.6)	0.029
Time interval (range; mo)	25.4 ± 4.2 (20–30)	22.1 ± 5.7 (10–28)	˂0.001

Notes: HIPEC, hyperthermic intraperitoneal chemotherapy. Time interval refers to time from surgery to peritoneal cavity recurrence.

Figure 1 Illness-specific DFS (A) and OS (B).